Three-gene prognostic classifier for early-stage non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 25, Issue 35, 2007, Pages 5562-5569

  Lau, Suzanne K ^a   Boutros, Paul C ^a   Pintilie, Melania ^a   Blackhall, Fiona H ^a   Zhu, Chang Qi ^a   Strumpf, Dan ^a   Johnston, Michael R ^a   Darling, Gail ^a   Keshavjee, Shaf ^a   Waddell, Thomas K ^a   Liu, Ni ^a   Lau, Davina ^a   Penn, Linda Z ^a   Shepherd, Frances A ^a   Jurisica, Igor ^a   Der, Sandy D ^a   Tsao, Ming Sound ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SYNTAXIN 1A;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CCR7; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNTAXIN 1; TUMOR MARKERS, BIOLOGICAL;

EID: 37649004550     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.0352     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Mountain CF: Staging classification of lung cancer: A critical evaluation. Clin Chest Med 23:103-121, 2002
3. Naruke T, Goya T, Tsuchiya R, et al: Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96:440-447, 1988
4. Wada H, Miyahara R, Tanaka F, et al: Post-operative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): A randomized clinical trial - West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 15:438-443, 1999
5. Dunant A, Pignon JP, Le Chevalier T: Adjuvant chemotherapy for non-small cell lung cancer: Contribution of the International Adjuvant Lung Trial. Clin Cancer Res 11:5017S-5021S, 2005
6. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
7. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22:621s, 2004 (suppl; abstr 7019)
8. Rosell R, de Lena M, Carpagnano F, et al: ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts). Lung Cancer 49:S3-S4, 2005 (suppl)
9. Singhal S, Vachani A, Antin-Ozerkis D, et al: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res 11:3974-3986, 2005
10. Zhu CQ, Shih W, Ling CH, et al: Immunohistochemical markers of prognosis in non-small cell lung cancer: A review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59:790-800, 2006
11. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790-13795, 2001
12. Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 98:13784-13789, 2001
13. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
14. Wigle DA, Jurisica I, Radulovich N, et al: Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62:3005-3008, 2002
15. Ramaswamy S, Ross KN, Lander ES, et al: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
16. Tomida S, Koshikawa K, Yatabe Y, et al: Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 23:5360-5370, 2004
17. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, et al: A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 10:2922-2927, 2004
18. Jiang H, Deng Y, Chen HS, et al: Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. BMC Bioinformatics 5:81, 2004
19. Ein-Dor L, Zuk O, Domany E: Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103:5923-5928, 2006
20. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357, 2006
21. Barsyte-Lovejoy D, Lau SK, Boutros PC, et al: The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 66:5330-5337, 2006
22. Blackhall FH, Wigle DA, Jurisica I, et al: Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. Lung Cancer 46:197-204, 2004
23. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121, 2001
24. Sultan M, Wigle DA, Cumbaa CA, et al: Binary tree-structured vector quantization approach to clustering and visualizing microarray data. Bioinformatics 18:S111-S119, 2002 (suppl 1)
25. Liu J, Blackhall F, Seiden-Long I, et al: Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. Oncogene 23:6316-6324, 2004
26. Yun JJ, Heisler LE, Hwang II, et al: Genomic DNA functions as a universal external standard in quantitative real-time PCR. Nucleic Acids Res 34:e85, 2006
27. Irizarry RA, Bolstad BM, Collin F, et al: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15, 2003
28. Endoh H, Tomida S, Yatabe Y, et al: Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 22:811-819, 2004
29. Chen HY, Yu SL, Chen CH, et al: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11-20, 2007
30. Brown KR, Jurisica I: Unequal evolutionary conservation of human protein interactions in interologous networks. Genome Biol 8:R95, 2007
31. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57:289-300, 1995
32. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570-580, 2006
33. Lu Y, Lemon W, Liu PY, et al: A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3:e467, 2006
34. Vandesompele J, De Preter K, Pattyn F, et al: Accurate normalization of real-time quantitative RTPCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034, 2002
35. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004
36. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
37. Grabowski P, Schonfelder J, Ahnert-Hilger G, et al: Expression of neuroendocrine markers: A signature of human undifferentiated carcinoma of the colon and rectum. Virchows Arch 441:256-263, 2002
38. Graff L, Castrop F, Bauer M, et al: Expression of vesicular monoamine transporters, synaptosomalassociated protein 25 and syntaxin1: A signature of human small cell lung carcinoma. Cancer Res 61:2138-2144, 2001
39. Bascom JL, Fata JE, Hirai Y, et al: Epimorphin overexpression in the mouse mammary gland promotes alveolar hyperplasia and mammary adenocarcinoma. Cancer Res 65:8617-8621, 2005
40. Mashino K, Sadanaga N, Yamaguchi H, et al: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 62:2937-2941, 2002
41. Schimanski CC, Schwald S, Simiantonaki N, et al: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11:1743-1750, 2005
42. Schimanski CC, Bahre R, Gockel I, et al: Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. Oncol Rep 16:109-113, 2006
43. Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis. Int J Cancer 105:186-189, 2003
44. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9:677-684, 2003
45. Pouyssegur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443, 2006
46. Chi JT, Wang Z, Nuyten DS, et al: Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med 3:e47, 2006
47. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5:845-856, 2005
48. Canales RD, Luo Y, Willey JC, et al: Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 24:1115-1122, 2006
49. Raponi M, Zhang Y, Yu J, et al: Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66:7466-7472, 2006
50. Verhaak RG, Staal FJ, Valk PJ, et al: The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. BMC Bioinformatics 7:105, 2006
51. Seo J, Hoffman EP: Probe set algorithms: Is there a rational best bet? BMC Bioinformatics 7:395, 2006
52. Simon R, Radmacher MD, Dobbin K, et al: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95:14-18, 2003
53. Simon R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332-7341, 2005
54. Dupuy A, Simon RM: Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99:147-157, 2007
55. Blackhall FH, Pintilie M, Wigle DA, et al: Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia 6:761-767, 2004
56. Cronin M, Sangli C, Liu M-L, et al: Analytical validation of the Oncotype/Dx genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptorpositive breast cancer. Clin Chem 53:1084-1091, 2007